Exonate aims to introduce a revolutionary, game-changing eye drop for the treatment of retinal vascular diseases, including wet Age-Related Macular Degeneration (wAMD) and Diabetic Macular Oedema (DMO), by using mRNA targeted therapies.
Exonate is leveraging expertise in our revolutionary, mRNA targeted, small molecule compounds. Our lead programme, for the treatment of Diabetic Macular Oedema (DMO), has entered Phase I clinical trials and we are actively developing targeted therapies across a range of diseases. By exploiting the alternative splicing of vascular endothelial growth factor (VEGF) we aim to use our cutting edge technology to introduce an Eye Drop to treat wet AMD and DMO. This has the potential to become the patients treatment of choice in an area of high medical unmet need. Our novel small molecule inhibitors have the ability to alter VEGF splicing in a number of indications in addition to our lead ophthalmology programme.
Today, wAMD is a leading cause of vision loss in people aged 60 years or older and affects more than 30 million patients worldwide, over 200,000 of those in the UK alone. If untreated patients are likely to lose sight in the affected eye within 24 months of disease onset. DMO is the build-up of fluid (oedema) in a region of the retina called the macula. DMO is the most common cause of vision loss among people with diabetic retinopathy. The global cost of visual impairment due to age-related macular degeneration – Exonate’s first therapeutic target area of ophthalmology – is $343 billion, including $255 billion in direct health care costs and is the most invested in area of ophthalmology by venture capitalists.en at any stage of the disease.
Exonate has received seed funding of £2.7m, and in 2017 received £4.9m Seeding Drug Discovery award by the Wellcome Trust. The ophthalmology scientific programme is funded through to start clinical development programme in 2020.